OptimizeRx First Quarter 2025 Earnings: Beats Expectations

OptimizeRx (NASDAQ:OPRX) First Quarter 2025 Results

Key Financial Results

• Revenue: US$21.9m (up 11% from 1Q 2024).
• Net loss: US$2.20m (loss narrowed by 68% from 1Q 2024).
• US$0.12 loss per share (improved from US$0.38 loss in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in OptimizeRx. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

OptimizeRx Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 67%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are up 18% from a week ago.

Risk Analysis

Be aware that OptimizeRx is showing 2 warning signs in our investment analysis and 1 of those is a bit concerning...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.